The Digital Frontier in Huntington's Disease: Opportunities for Clinical Trials

Area of Science:

• Neuroscience
• Biomedical Engineering
• Clinical Research

Background:

• Huntington's disease (HD) requires sensitive measures for early progression assessment.
• Current clinical endpoints lack sensitivity for early HD detection.
• Digital measures offer objective and sensitive assessments for early HD impairments.

Purpose of the Study:

• Review the current state of digital measures in HD research.
• Propose a roadmap for future research on digital measures in HD.
• Evaluate the potential of digital measures as clinical trial endpoints in HD.

Main Methods:

• Literature review of digital measures in neurodegenerative diseases, focusing on HD.
• Analysis of studies on portable and wearable devices for continuous data collection.
• Examination of the relationship between digital measures and health outcomes.

Main Results:

• Digital measures show promise for early-stage HD clinical trials.
• More research is needed on longitudinal performance and sensitivity to disease progression.
• Digital health technologies can provide continuous, real-life performance data.

Conclusions:

• Digital measures have potential as monitoring and response biomarkers in HD clinical research.
• Validation and regulatory considerations are crucial for digital measures as clinical trial endpoints.
• Future research must establish digital measures as sensitive, meaningful endpoints for early HD, integrating them with patient-reported outcomes.